دورية أكاديمية
Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy.
| العنوان: | Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy. |
|---|---|
| المؤلفون: | Linde MH; Immunology Graduate Program, Stanford University School of Medicine, Stanford, California.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Fan AC; Immunology Graduate Program, Stanford University School of Medicine, Stanford, California.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Köhnke T; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Trotman-Grant AC; Immunology Graduate Program, Stanford University School of Medicine, Stanford, California.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Gurev SF; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Phan P; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Zhao F; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Haddock NL; Immunology Graduate Program, Stanford University School of Medicine, Stanford, California., Nuno KA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Gars EJ; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California.; Department of Pathology, Stanford University, Stanford, California., Stafford M; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Marshall PL; Immunology Graduate Program, Stanford University School of Medicine, Stanford, California., Dove CG; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Linde IL; Immunology Graduate Program, Stanford University School of Medicine, Stanford, California.; Department of Pathology, Stanford University, Stanford, California., Landberg N; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Miller LP; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Majzner RG; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Pediatrics, Stanford University School of Medicine, Stanford, California., Zhang TY; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California., Majeti R; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California. |
| المصدر: | Cancer discovery [Cancer Discov] 2023 May 04; Vol. 13 (5), pp. 1164-1185. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : American Association for Cancer Research |
| مواضيع طبية MeSH: | Neoplasms*/therapy , Leukemia* , Cancer Vaccines*, Animals ; Mice ; Antigen-Presenting Cells ; Antigens, Neoplasm ; Immunotherapy |
| مستخلص: | Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAA) and eradicating malignant cells. Here, we present a cancer vaccination approach utilizing myeloid-lineage reprogramming to directly convert cancer cells into tumor-reprogrammed antigen-presenting cells (TR-APC). Using syngeneic murine leukemia models, we demonstrate that TR-APCs acquire both myeloid phenotype and function, process and present endogenous TAAs, and potently stimulate TAA-specific CD4+ and CD8+ T cells. In vivo TR-APC induction elicits clonal expansion of cancer-specific T cells, establishes cancer-specific immune memory, and ultimately promotes leukemia eradication. We further show that both hematologic cancers and solid tumors, including sarcomas and carcinomas, are amenable to myeloid-lineage reprogramming into TR-APCs. Finally, we demonstrate the clinical applicability of this approach by generating TR-APCs from primary clinical specimens and stimulating autologous patient-derived T cells. Thus, TR-APCs represent a cancer vaccination therapeutic strategy with broad implications for clinical immuno-oncology. Significance: Despite recent advances, the clinical benefit provided by cancer vaccination remains limited. We present a cancer vaccination approach leveraging myeloid-lineage reprogramming of cancer cells into APCs, which subsequently activate anticancer immunity through presentation of self-derived cancer antigens. Both hematologic and solid malignancies derive significant therapeutic benefit from reprogramming-based immunotherapy. This article is highlighted in the In This Issue feature, p. 1027. (©2023 American Association for Cancer Research.) |
| معلومات مُعتمدة: | K08 CA248940 United States CA NCI NIH HHS; F31 CA196029 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Antigens, Neoplasm) 0 (Cancer Vaccines) |
| تواريخ الأحداث: | Date Created: 20230301 Date Completed: 20230505 Latest Revision: 20230507 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1158/2159-8290.CD-21-0502 |
| PMID: | 36856575 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2159-8290 |
|---|---|
| DOI: | 10.1158/2159-8290.CD-21-0502 |